This year’s LESI conference focused on how licensing executives can best commercialise IP in a time of rapid technological change.
Andy Richards, a biotechnology entrepreneur and chairman and director of various Cambridge-based biotechnology companies, chaired a panel that looked at the challenges facing 21st century life sciences companies.
Richards said that many of the new technologies being invented do not fit current licensing business models. The life sciences market is further complicated by companies such as Google and Microsoft entering a market (through research funding) already populated by mainstays such as GE.
New business ventures from emerging markets may add to this because it is unclear “what form those will take”, he said.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email James Lynn on firstname.lastname@example.org.
LESI conference 2011, life sciences, technology